Comparison

CJC-1295 vs. GHRP-2

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

CJC-1295

Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.

GHRP-2

GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.

Evidence base

Highest evidence

Human trial

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	CJC-1295	GHRP-2
Germany	Unapproved	Unapproved
JP	—	Prescription
United States	Research only	Unapproved

Full entries

Frequently asked questions

What is the difference between CJC-1295 and GHRP-2?: CJC-1295 is classified as "Growth", while GHRP-2 is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. GHRP-2: Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CJC-1295 or GHRP-2?: The highest available evidence level is "Human trial" for CJC-1295 and "Human trial" for GHRP-2. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CJC-1295 and GHRP-2 in Germany and the United States?: Germany: CJC-1295 — Unapproved, GHRP-2 — Unapproved. United States: CJC-1295 — Research only, GHRP-2 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

CJC-1295

GHRP-2

Germany

Unapproved

—

Prescription

United States

Research only

Unapproved

Frequently asked questions

What is the difference between CJC-1295 and GHRP-2?

CJC-1295 is classified as "Growth", while GHRP-2 is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. GHRP-2: Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CJC-1295 or GHRP-2?

The highest available evidence level is "Human trial" for CJC-1295 and "Human trial" for GHRP-2. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CJC-1295 and GHRP-2 in Germany and the United States?

Germany: CJC-1295 — Unapproved, GHRP-2 — Unapproved. United States: CJC-1295 — Research only, GHRP-2 — Unapproved. These are factual summaries with source and review date on the individual pages.